Endo Presses On With Generic OxyContin Despite Risks
Endo Pharmaceuticals' risk-fraught decision to continue marketing its generic version of painkiller OxyContin even after losing a patent challenge at the Federal Circuit shows just how far the generics industry is...To view the full article, register now.
Already a subscriber? Click here to view full article